IP Library › Patent Application 15973903
Patent Application
App. No. 15/973,903

Compositions and Methods for Spine Fusion Procedures

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/973,903
Abstract

The present invention provides compositions and methods for promoting fusion of bones in spine fusion procedures. In some embodiments, a method of performing a spine fusion procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired spine fusion.

Claims (27)

1 . A method of promoting bone fusion in a spine fusion procedure, comprising administering to a site of desired spine fusion a composition comprising: a biocompatible matrix and a solution comprising platelet derived growth factor (PDGF), wherein the solution is incorporated in the biocompatible matrix, wherein the biocompatible matrix comprises a bone scaffolding material, and wherein the bone scaffolding material comprises a porous calcium phosphate or allograft.

2 . The method according to claim 1 , wherein the bone scaffolding material comprises calcium phosphate.

3 . The method according to claim 1 , wherein the calcium phosphate comprises @-tricalcium phosphate.

4 . The method according to claim 1 , wherein the bone scaffolding material comprises allograft.

5 . The method according to claim 1 , wherein the PDGF is present in the solution at a concentration from about 0.01 mg/ml to about 10.0 mg/ml.

6 . The method according to claim 1 , wherein the PDGF is present in the solution at a concentration from about 0.05 mg/ml to about 5.0 mg/ml.

7 . The method according to claim 1 , wherein the PDGF is present in the solution at a concentration from about 0.1 mg/ml to about 1.0 mg/ml.

8 . The method according to claim 1 , wherein the PDGF is present in the solution at a concentration from about 0.2 mg/ml to about 0.4 mg/ml.

9 . The method according to claim 1 , wherein the PDGF is present in the solution at a concentration of about 0.3 mg/ml.

10 . The method according to claim 1 , wherein the PDGF comprises PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD, or a mixture or a derivative thereof.

11 . The method according to claim 1 , wherein the PDGF comprises PDGF-BB.

12 . (canceled)

13 . The method according to claim 1 , wherein the PDGF-BB comprises at least 65% intact PDGF-BB.

14 . The method according to claim 1 , wherein the PDGF-BB is recombinant human (rh)PDGF-BB.

15 - 17 . (canceled)

18 . The method according to claim 1 , wherein the bone scaffolding material comprises particles in a range of about 50 microns to about 5000 microns in size.

19 . (canceled)

20 . The method according to claim 1 , wherein the bone scaffolding material comprises particles in a range of about 100 microns to about 5000 microns in size.

21 . (canceled)

22 . The method according to claim 1 , wherein the bone scaffolding material comprises particles in a range of about 100 microns to about 300 microns in size.

23 . (canceled)

24 . The method according to claim 1 , wherein the bone scaffolding material comprises particles in a range of about 1000 microns to about 2000 microns in size.

25 . (canceled)

26 . The method according to claim 1 , wherein the bone scaffolding material comprises particles in a range of about 250 microns to about 1000 microns in size.

27 . (canceled)

28 . The method according to claim 1 , wherein the bone scaffolding material comprises particles in a range of about 1000 microns to about 3000 microns in size.

29 - 114 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2019
From: LYNCH, SAMUEL E.; SNEL, LEO B.; HEE, CHRISTOPHER K.
To: BIOMIMETIC THERAPEUTICS, LLC
Reel/Frame 050204/0682 →